ALERT | Cardiovascular Disease and COVID-19 READ MORE

Our Promise

One pill, one bottle, one prescription, one refill, one dispensing fee, one co-pay, once-a-day.

CardioPharma, Inc. is focused on the global development of combinatorial cardiovascular products aimed at reducing the morbidity and mortality of the world’s number one killer – cardiovascular disease – in a cost-effective manner.

According to the American Heart Association, there are 121.5 million cardiovascular patients in the US alone suffering from disorders that encompass the leading cause of all US deaths. Further, these disorders cost the US over $351.3 billion each year.1 Globally, the number of patients and the related healthcare costs are even more staggering.

Relatedly, many experts believe the number one problem in medicine is patients not taking their medications or not taking them as prescribed, i.e., pharmaceutical non-compliance. Estimates are that as many as 60% of cardiovascular patients do not take their medications as they should. 2

There continues to be much published research into adherence, specifically in the area of cardiovascular disease. Of note are two large meta-analyses 3,4 the larger of which concluded that: “a considerable proportion of all CVD events could be attributed to poor adherence to vascular medications alone, and that the level of optimal adherence confers a significant inverse association with subsequent adverse outcomes.”

The CardioPharma pipeline takes aim at significant medical needs – in a cost-effective manner – for patients, providers, pharmacists and payers around the world. The pipeline of CardioPharma is dedicated to developing cardiovascular products which provide improved compliance, reduced costs and convenience, in order to help mitigate the human and financial costs of the world’s cardiovascular disease epidemic.

ConvenienceImproved ComplianceReduced Costs
1 – American Heart Association Heart Disease and Stroke Statistics – 2020 update
2 – Circulation 2010;121:1455-1458
3 – Naderi SH, Adherence to Drugs that Prevent Cardiovascular Disease: Meta-analysis on 376,162 patients. American Journal of Medicine (2012) 125: 882-887
4 – Chowdhury R, Adherence to Cardiovascular Therapy: a meta-analysis of prevalence and clinical consequences. European Heart Journal. (2013) 34: 2940-2948